A recent study found that children who used the weight loss drug liraglutide lost significantly more weight compared to those given a placebo. This late-stage trial focused on children aged 6 to 12 with high BMI, showing promising results for younger children. Liraglutide, already approved for adults and older teens, may help younger children reduce body mass index (BMI) significantly, highlighting the potential benefits of early intervention. However, the study noted some side effects, including stomach issues, which were generally manageable.
Obesity is considered the most common chronic health problem among children in the United States.
The trial included 82 children, and those receiving liraglutide showed a 5.8% drop in BMI, while the placebo group experienced a 1.6% increase. The study indicates that treating obesity in children could lead to better long-term health outcomes. Experts stress the need for further research to understand long-term effects and ensure safety, especially since obesity is a chronic condition that often persists into adulthood, leading to various health problems. Though controversial, liraglutide's positive impact in managing childhood obesity could provide a valuable tool alongside behavioral interventions.
